Arsenic trioxide inhibits Ewing's sarcoma cell invasiveness by targeting p38 MAPK and c-Jun N-terminal kinase

Anti-Cancer Drugs

Volumn 23, Issue 1, 2012, Pages 108-118

  Zhang, Shuai ^a   Guo, Wei ^a   Ren, Ting Ting ^a   Lu, Xin Chang ^a   Tang, Guo Qing ^a   Zhao, Fu Long ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

arsenic trioxide; Ewing's sarcoma; invasion; migration; mitogenactivated protein kinase

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANISOMYCIN; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ARSENIC TRIOXIDE; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE;

ACTIN FILAMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INVASION; CELL ADHESION; CELL INVASION; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; EWING SARCOMA; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; METASTASIS INHIBITION; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANISOMYCIN; ANTINEOPLASTIC AGENTS; ARSENICALS; BONE NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CYTOSKELETON; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MATRIX METALLOPROTEINASE 9; OXIDES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; SARCOMA, EWING;

EID: 82555166027     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834bfd68     Document Type: Article

References (44)

1. Ludwig JA. Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol 2008; 20:412-418.
2. Bacci G, Forni C, Longhi A, Ferrari S, Donati D, De Paolis M, et al. Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies: 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer 2004; 40:73-83. (Pubitemid 37542320)
3. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348:694-701. (Pubitemid 36237038)
4. Kolb EA, Kushner BH, Gorlick R, Laverdiere C, Healey JH, LaQuaglia MP, et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 2003; 21: 3423-3430. (Pubitemid 46594075)
5. Esiashvili N, Goodman M, Marcus RB Jr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance epidemiology and end results data. J Pediatr Hematol Oncol 2008; 30:425-430.
6. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89:3354-3360.
7. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339:1341-1348. (Pubitemid 28509343)
8. Jung HS, Kim HS, Lee MJ, Shin HY, Ahn HS, Ryu KH, et al. Arsenic trioxide concentration determines the fate of Ewing's sarcoma family tumors and neuroblastoma cells in vitro. FEBS Lett 2006; 580:4969-4975. (Pubitemid 44286843)
9. Zhu J, Chen Z, Lallemand-Breitenbach V, de The H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer 2002; 2: 705-713. (Pubitemid 37328921)
10. Guo W, Tang XD, Tang S, Yang Y. Preliminary report of combination chemotherapy including arsenic trioxide for stage III osteosarcoma and Ewing sarcoma. Zhonghua Wai Ke Za Zhi 2006; 44:805-808.
11. Tingting R, Wei G, Changliang P, Xinchang L, Yi Y. Arsenic trioxide inhibits osteosarcoma cell invasiveness via MAPK signaling pathway. Cancer Biol Ther 2010; 10:251-257.
12. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62:3893-3903. (Pubitemid 34792653)
13. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000; 351 (Pt 2):289-305.
14. Saito H. Regulation of cross-talk in yeast MAPK signaling pathways. Curr Opin Microbiol 2010; 13:677-683.
15. Kajiguchi T, Yamamoto K, Hossain K, Akhand AA, Nakashima I, Naoe T, et al. Sustained activation of c-jun-terminal kinase (JNK) is closely related to arsenic trioxide-induced apoptosis in an acute myeloid leukemia (M2)-derived cell line, NKM-1. Leukemia 2003; 17:2189-2195. (Pubitemid 37428385)
16. 2+-induced ERK activation mediated by reactive oxygen species causes cell death in differentiated PC12 cells. J Neurochem 2001; 78:600-610. (Pubitemid 32729988)
17. Tang GQ, Yan TQ, Guo W, Ren TT, Peng CL, Zhao H, et al. (-)-Epigallocatechin-3-gallate induces apoptosis and suppresses proliferation by inhibiting the human Indian Hedgehog pathway in human chondrosarcoma cells. J Cancer Res Clin Oncol 2010; 136: 1179-1185.
18. Larsson C. Protein kinase C and the regulation of the actin cytoskeleton. Cell Signal 2006; 18:276-284. (Pubitemid 41661343)
19. Birkedal-Hansen H, Moore WG, Bodden MK,Windsor LJ, Birkedal-Hansen B, DeCarlo A, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4:197-250. (Pubitemid 23103292)
20. Reynolds JJ. Collagenases and tissue inhibitors of metalloproteinases: a functional balance in tissue degradation. Oral Dis 1996; 2:70-76. (Pubitemid 126602152)
21. Bode A, Dong Z. Apoptosis induction by arsenic: mechanisms of action and possible clinical applications for treating therapy-resistant cancers. Drug Resist Updat 2000; 3:21-29. (Pubitemid 30246565)
22. Eguchi R, Fujimori Y, Takeda H, Tabata C, Ohta T, Kuribayashi K, et al. Arsenic trioxide induces apoptosis through JNK and ERK in human mesothelioma cells. J Cell Physiol 2011; 226:762-768.
23. Wang X, Ren JH, Lin F,Wei JX, Long M, Yan L, et al. Stathmin is involved in arsenic trioxide-induced apoptosis in human cervical cancer cell lines via PI3K linked signal pathway. Cancer Biol Ther 2010; 10:632-643.
24. Park MJ, Lee JY, Kwak HJ, Park CM, Lee HC,Woo SH, et al. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species. J Cell Biochem 2005; 95:955-969. (Pubitemid 41420143)
25. Wei LH, Lai KP, Chen CA, Cheng CH, Huang YJ, Chou CH, et al. Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor kappaB. Oncogene 2005; 24:390-398.
26. Le Deley MC, Delattre O, Schaefer KL, Burchill SA, Koehler G, Hogendoorn PC, et al. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol 2010; 28:1982-1988.
27. Paulussen M, Ahrens S, Craft AW, Dunst J, Frohlich B, Jabar S, et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol 1998; 16:3044-3052. (Pubitemid 28417425)
28. Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, Lee YC, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest 2011; 121: 148-160.
29. Lin TH, Kuo HC, Chou FP, Lu FJ. Berberine enhances inhibition of glioma tumor cell migration and invasiveness mediated by arsenic trioxide. BMC Cancer 2008; 8:58.
30. Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 1990; 9:289-303.
31. Ho SY,Wu WJ, Chiu HW, Chen YA, Ho YS, Guo HR, et al. Arsenic trioxide and radiation enhance apoptotic effects in HL-60 cells through increased ROS generation and regulation of JNK and p38 MAPK signaling pathways. Chem Biol Interact 2011; 193:162-171.
32. Liu B, Pan S, Dong X, Qiao H, Jiang H, Krissansen GW, et al. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci 2006; 97:675-681. (Pubitemid 44056616)
33. Huang HS, Liu ZM, Hong DY. Blockage of JNK pathway enhances arsenic trioxide-induced apoptosis in human keratinocytes. Toxicol Appl Pharmacol 2010; 244:234-241.
34. Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, et al. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem 1996; 271:10672-10680.
35. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000; 14:2123-2133.
36. Huang C, Rajfur Z, Borchers C, Schaller MD, Jacobson K. JNK phosphorylates paxillin and regulates cell migration. Nature 2003; 424:219-223. (Pubitemid 36858692)
37. Lee Y, Kim H, Kim S, Kim KH, Chung JH. Activation of toll-like receptors 2, 3 or 5 induces matrix metalloproteinase-1 and -9 expression with the involvement of MAPKs and NF-kappaB in human epidermal keratinocytes. Exp Dermatol 2010; 19: e44-e49.
38. Mitra S, Lee JS, Cantrell M, Van den Berg CL. c-Jun N-terminal kinase 2 (JNK2) enhances cell migration through epidermal growth factor substrate 8 (EPS8). J Biol Chem 2011; 286:15287-15297.
39. Lu MK, Shih YW, Chang Chien TT, Fang LH, Huang HC, Chen PS. alpha-Solanine inhibits human melanoma cell migration and invasion by reducing matrix metalloproteinase-2/9 activities. Biol Pharm Bull 2010; 33:1685-1691.
40. Kumar B, Koul S, Petersen J, Khandrika L, Hwa JS, Meacham RB, et al. p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Res 2010; 70:832-841.
41. Rosser EM, Morton S, Ashton KS, Cohen P, Hulme AN. Synthetic anisomycin analogues activating the JNK/SAPK1 and p38/SAPK2 pathways. Org Biomol Chem 2004; 2:142-149.
42. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991; 1072: 129-157. (Pubitemid 121007534)
43. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995; 270:16483-16486.
44. Tanos T, Marinissen MJ, Leskow FC, Hochbaum D, Martinetto H, Gutkind JS, et al. Phosphorylation of c-Fos by members of the p38 MAPK family: role in the AP-1 response to UV light. J Biol Chem 2005; 280: 18842-18852. (Pubitemid 41379586)